Advertisement

Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80
Document › Details

Roslin Cell Therapies Ltd. (RoslinCT). (1/11/16). "Press Release: Roslin Cells Announces the Creation of Two Commercially-focused Subsidiaries".

Region Region Roslin, Midlothian
  Country United Kingdom (GB)
Organisations Organisation Roslin Cell Therapies Ltd. (RoslinCT)
  Organisation 2 Roslin Cells Ltd.
  Group Roslin Institute
Products Product cell therapy
  Product 2 iPSC technology (induced pluripotent stem cell technology)
Persons Person Courtney, Aidan (Roslin Cells 201111 CEO)
  Person 2 Bellot, Fiona (Roslin Cell Therapies 201601– Business Development Manager)
     


Roslin Cells Ltd., the Edinburgh and Cambridge based spin out from the world renowned Roslin Institute, announced today that it has established two subsidiary companies to accelerate the expansion of its commercial operations.

Roslin Cell Therapies will carry forward its process development and manufacture of cell therapies for clinical trials. Roslin Cell Sciences will focus on the production and use of human induced Pluripotent Stem Cells (iPSCs) for drug discovery.


Roslin Cell Therapies

Roslin Cell Therapies builds on the wealth of expertise and industry recognition developed by Roslin Cells in the process development and manufacture of Cell Therapies and Advanced Therapy Medicinal Products (ATMPs). Based at Edinburgh BioQuarter, where it operates purpose built clean room facilities, the company will continue to provide contract manufacturing services for clinical trial supply.


Roslin Cell Sciences

Roslin Cell Sciences will focus on further development of Roslin Cells’ expertise in the creation of induced Pluripotent Stem Cells (iPSCs) for commercial and academic drug research. There is an increasing appreciation that iPSCs offer a wholly new means of evaluating new drugs and their suitability for particular patients. With facilities in both Edinburgh and Cambridge, UK, the company is capable of creating large numbers of iPS cell lines from cohorts of donors. Creating cell lines in this way will enable researchers to understand better how drug performance varies between individuals due to their genetic variation.


Aidan Courtney, Chief Executive Officer stated “Since we founded the company in 2006, it has developed two distinct businesses both operating in rapidly developing markets – the manufacture of cell therapies and the use of iPSCs for research. By creating two separate commercial entities, we will be best placed to maximise the growth and success of both.”


Press Contacts

For more information, please contact:

Roslin Cell Therapies
Fiona Bellot, Business Development Manager
Tel: +44 (0)131 658 5180
Mobile: +44 (0)7867494071
Email: fiona.bellot@roslinct.com
Web : www.roslinct.com

Roslin Cell Sciences
Kevin Bruce, Head of Commercial
Tel: +44 (0)131 440 6543
Mobile: +44 (0)7825 393 287
Email: kevin.bruce@roslincs.com
Web: www.roslincells.com/roslincellsciences

   
Record changed: 2020-06-28

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Roslin Cell Therapies Ltd. (RoslinCT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top